Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion type Assertion NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_head.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion description "[For biliopancreatic malignancy, following CEA as more historical and basic TM of gastrointestinal diseases, the mainstay marker is CA 19-9 as monosialo-ganglioside/glycolipid and sialyl derivative of lacto-N-fucopentaose II (sialyl-Lewis(a), hapten of human Lewis(a) bloodgroup determinant).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion evidence source_evidence_literature NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion SIO_000772 10436809 NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion wasDerivedFrom befree-20140225 NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.
- NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_assertion wasGeneratedBy ECO_0000203 NP702298.RAFOwnOvRLPrF6uXeCuM5AUxEnMc1pBObNgAyezA0xJEU130_provenance.